Association Between Clinical Characteristics and Clinical Relapse in the Evaluation Cohort
| Factors . | Univariable analysis . | . | . | Multivariable analysis . | . | . |
|---|---|---|---|---|---|---|
| . | HR . | (95% CI) . | P Value . | HR . | (95% CI) . | P Value . |
| Age (≥ 30 vs < 30 y) | 1.514 | (.767–2.988) | .234 | … | … | |
| Sex (male vs female) | 2.988 | (1.058–8.437) | .040 | … | … | |
| Genotype (B vs C) | 1.115 | (.570–2.180) | .752 | … | … | |
| Treatment duration (< 3 vs ≥ 3 y) | 1.196 | (.606–2.363) | .607 | … | … | |
| Consolidation duration (< 2 vs ≥ 2 y) | 1.201 | (.545–2.647) | .651 | … | … | |
| EOT HBsAg level (≥ 2 vs < 2 log10 IU/mL) | 1.461 | (.353–6.052) | .603 | … | … | |
| EOT HBV DNA (positive vs negative) | 2.642 | (1.267–5.510) | .010 | … | … | |
| EOT HBV RNA (positive vs negative) | 4.116 | (1.457–11.630) | .008 | 3.580 | (1.264–10.135) | .017 |
| EOT HBcrAg level (≥ 4 vs < 4 log10 U/mL) | 6.548 | (1.580–27.142) | .010 | 5.696 | (1.371–23.670) | .017 |
| Factors . | Univariable analysis . | . | . | Multivariable analysis . | . | . |
|---|---|---|---|---|---|---|
| . | HR . | (95% CI) . | P Value . | HR . | (95% CI) . | P Value . |
| Age (≥ 30 vs < 30 y) | 1.514 | (.767–2.988) | .234 | … | … | |
| Sex (male vs female) | 2.988 | (1.058–8.437) | .040 | … | … | |
| Genotype (B vs C) | 1.115 | (.570–2.180) | .752 | … | … | |
| Treatment duration (< 3 vs ≥ 3 y) | 1.196 | (.606–2.363) | .607 | … | … | |
| Consolidation duration (< 2 vs ≥ 2 y) | 1.201 | (.545–2.647) | .651 | … | … | |
| EOT HBsAg level (≥ 2 vs < 2 log10 IU/mL) | 1.461 | (.353–6.052) | .603 | … | … | |
| EOT HBV DNA (positive vs negative) | 2.642 | (1.267–5.510) | .010 | … | … | |
| EOT HBV RNA (positive vs negative) | 4.116 | (1.457–11.630) | .008 | 3.580 | (1.264–10.135) | .017 |
| EOT HBcrAg level (≥ 4 vs < 4 log10 U/mL) | 6.548 | (1.580–27.142) | .010 | 5.696 | (1.371–23.670) | .017 |
Abbreviations: CI, confidence interval; EOT, end of treatment; HBcrAg, hepatitis B core–related antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HR, hazard ratio.
Association Between Clinical Characteristics and Clinical Relapse in the Evaluation Cohort
| Factors . | Univariable analysis . | . | . | Multivariable analysis . | . | . |
|---|---|---|---|---|---|---|
| . | HR . | (95% CI) . | P Value . | HR . | (95% CI) . | P Value . |
| Age (≥ 30 vs < 30 y) | 1.514 | (.767–2.988) | .234 | … | … | |
| Sex (male vs female) | 2.988 | (1.058–8.437) | .040 | … | … | |
| Genotype (B vs C) | 1.115 | (.570–2.180) | .752 | … | … | |
| Treatment duration (< 3 vs ≥ 3 y) | 1.196 | (.606–2.363) | .607 | … | … | |
| Consolidation duration (< 2 vs ≥ 2 y) | 1.201 | (.545–2.647) | .651 | … | … | |
| EOT HBsAg level (≥ 2 vs < 2 log10 IU/mL) | 1.461 | (.353–6.052) | .603 | … | … | |
| EOT HBV DNA (positive vs negative) | 2.642 | (1.267–5.510) | .010 | … | … | |
| EOT HBV RNA (positive vs negative) | 4.116 | (1.457–11.630) | .008 | 3.580 | (1.264–10.135) | .017 |
| EOT HBcrAg level (≥ 4 vs < 4 log10 U/mL) | 6.548 | (1.580–27.142) | .010 | 5.696 | (1.371–23.670) | .017 |
| Factors . | Univariable analysis . | . | . | Multivariable analysis . | . | . |
|---|---|---|---|---|---|---|
| . | HR . | (95% CI) . | P Value . | HR . | (95% CI) . | P Value . |
| Age (≥ 30 vs < 30 y) | 1.514 | (.767–2.988) | .234 | … | … | |
| Sex (male vs female) | 2.988 | (1.058–8.437) | .040 | … | … | |
| Genotype (B vs C) | 1.115 | (.570–2.180) | .752 | … | … | |
| Treatment duration (< 3 vs ≥ 3 y) | 1.196 | (.606–2.363) | .607 | … | … | |
| Consolidation duration (< 2 vs ≥ 2 y) | 1.201 | (.545–2.647) | .651 | … | … | |
| EOT HBsAg level (≥ 2 vs < 2 log10 IU/mL) | 1.461 | (.353–6.052) | .603 | … | … | |
| EOT HBV DNA (positive vs negative) | 2.642 | (1.267–5.510) | .010 | … | … | |
| EOT HBV RNA (positive vs negative) | 4.116 | (1.457–11.630) | .008 | 3.580 | (1.264–10.135) | .017 |
| EOT HBcrAg level (≥ 4 vs < 4 log10 U/mL) | 6.548 | (1.580–27.142) | .010 | 5.696 | (1.371–23.670) | .017 |
Abbreviations: CI, confidence interval; EOT, end of treatment; HBcrAg, hepatitis B core–related antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HR, hazard ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
